Observational studyBMC cancer2025
Prevalence and factors associated with chemotherapy-induced adverse events in cancer treatment centers in Amhara national regional state comprehensive referral hospitals, 2024: multicenter prospective follow up study.
Observational study in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Pharmacogenomic variation and chemotherapy-related toxicity profiles in pediatric patients with cancer in Tanzania: a cross-sectional study.Frontiers in pharmacology · 2026Article
- Comments on: 'The Impact of Gratitude Combined with Relaxation Therapy on Anxiety Reduction in Breast Cancer Patients Undergoing Chemotherapy: A Comparative Study'.Indian journal of palliative careArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChemotherapy drugs remain the gold standard treatment for cancer. However, the side effects limit chemotherapy treatment and make treatment outcome poor. This makes chemotherapy side effects a big public health problem globally.
objectiveTo assess prevalence and factors associated with chemotherapy-induced adverse events in cancer treatment centers in Amhara national regional state comprehensive referral hospitals, Norwest Ethiopia 2024. METHODOLOGY: Multi-center prospective observational study was conducted. Data was collected using questionnaire and checklist. Adverse events were collected and graded using National Cancer Institute Common Terminology CTCAE version 4.0. Data was transformed from Epi data to SPSS and logistic regression analysis was done. Both crude and adjusted odds ratio were used to assess the strength of association. Variables with a p-value of less than 0.05 were considered as statistically significant.
resultsA total of 572 patients were included in the study with a response rate of 99.5%. The overall prevalence of chemotherapy related adverse events was 78.49% with (95%, CI = 0.7783–0.7817). Cisplatin causes adverse events in 152 (95%), oxaliplatin 59 (100%), paclitaxel 28 (100%), docetaxel 42 (76.4%), gemcitabine 68 (68%) patients, 5-Flurouracil 65 (51.2%) and cyclophosphamide 10 (29.4%) patients respectively. The commonest severe (grades 3–4) adverse events were peripheral neuropathy or pain (36.7%), nausea and vomiting (28.5%), hair loss (22.9%), fatigue (22%), itching (19.1%), cyanosis (18%), leukopenia (16.9%) and diarrhea (16.3%). Being female (AOR = 4.201, CI = 2.580–6.217), history of motion (AOR = 3.001, CI = 2.410–5.201), history of morning sickness (AOR = 1.610, CI = 101 − 3.1), second cycle chemotherapy (AOR = 2.701, CI = 201 − 8.09) and third cycle of chemotherapy (AOR = 3.201, CI = 2.91–5.302) were associated with chemotherapy related adverse events. CONCLUSION AND RECOMMENDATIONS: The prevalence of chemotherapy-induced adverse events was high in the study settings. We recommend early cycle by cycle risk assessment of patients and management of adverse events. Additionally, training should be given for oncologic nurses about the risk assessment and management of adverse events. High emphasis should be given for patients who will receive oxaliplatin, cisplatin, paclitaxel, docetaxel and gemcitabine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.